The challenge for biosimilars companies like Sandoz is to bring to market medicines based around larger, more complex proteins and monoclonal antibodies ... “This type of data can give ...

The denosumab biosimilar market is poised for disruption with 3 FDA-approved biosimilars, at least 5 awaiting approval, and ...

the monoclonal antibody market is witnessing a surge in biosimilar approvals. Biosimilars provide a cost-effective alternative to expensive branded biologics, increasing accessibility for patients ...

Forty-one of those biosimilars have launched in the U.S. market. These record-breaking numbers reflect a growing momentum in acceptance and integration of biosimilars into the U.S. market that has ...

is the first monoclonal antibody biosimilar therapy and has been the most established biosimilar treatment in the Canadian market for over 10 years Decision reflects Celltrion’s ongoing ...

The latest research report published by Vantage Market Research, titled "An Increase in Demand and Opportunities for the Global Biosimilars Market 2025-2035," provides a comprehensive analysis of the ...

The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market ... is a humanized IgG1 monoclonal antibody that acts as an interleukin ...

Almost undoubtedly, these types of agents ... Antidrug antibodies may interfere with the efficacy of these agents. Future therapies will hopefully include cheaper biosimilars, which have only ...

Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...

The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives.